Prevalence, contemporary trends and associated factors of potentially inappropriate prescription of edoxaban in real‐world clinical practice: A subanalysis of the SUNSHINE registry
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AIM: As the direct oral anticoagulant most recently approved in China, data pertaining to clinical edoxaban use are still scarce. This study investigated the prevalence of and contemporary trends in edoxaban prescription among Chinese patients as well as factors associated with its inappropriate use in a multicentre registry of patients treated in real-world clinical practice. METHODS: This real-world, prospective, multicentre and non-interventional study included 1005 inpatients treated with edoxaban. According to National Medical Products Administration and European Heart Rhythm Association guidelines, edoxaban therapy was determined to be appropriate or inappropriate in each case. RESULTS: The median patient age was 70.0 years (interquartile range 61.0-78.0 years) and 46.3% were women. Overall, 456 (45.4%) patients received inappropriate edoxaban therapy, and common issues included an inappropriately low dosage (183, 18.2%) or wrong drug selection (109, 10.8%), high dosage (73, 7.3%), unreasonable off-label use (49, 4.9%), contraindicated medication combinations (27, 2.7%) and incorrect administration timing (16, 1.6%). Several factors, such as age ≥75 years (odds ratio [OR] = 1.921, 95% confidence interval [CI] 1.355-2.723, P < 0.001), weight >60 kg (OR = 2.657, 95%CI 1.970-3.583, P < 0.001), severe renal insufficiency (OR = 1.988, 95% CI 1.043-3.790, P = 0.037), current anaemia (OR = 1.556, 95% CI 1.151-2.102, P = 0.004) and history of bleeding (OR = 2.931, 95% CI 1.605-5.351, P < 0.001) were associated with an increased risk of inappropriate edoxaban therapy, whereas factors associated with cardiovascular specialties, such as admission to a cardiovascular department (OR = 0.637, 95% CI 0.464-0.873, P = 0.005), dronedarone use (OR = 0.065, 95% CI 0.026-0.165, P < 0.001) and amiodarone use (OR = 0.365, 95% CI 0.209-0.637, P < 0.001) decreased this risk. CONCLUSION: In this real-world study, 45.4% of patients received an inappropriate treatment with edoxaban. Multiple clinical characteristics can help identify patients who should receive edoxaban. Further development and implantation of educational activities and management strategies are needed to ensure the correct use of edoxaban.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prevalence, contemporary trends and associated factors of potentially inappropriate prescription of edoxaban in real‐world clinical practice: A subanalysis of the SUNSHINE registry
- Date Crossref
- 13/12/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Henan University pays non établi dans la noticeUniversité ou école supérieure
-
Zhengzhou University Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Henan Provincial People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Fujian Medical University Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
First Affiliated Hospital of Fujian Medical University pays non établi dans la noticeÉtablissement de santé
-
Ningde Normal University Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Zhengzhou Central Hospital pays non établi dans la noticeÉtablissement de santé
-
Capital Medical University Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Beijing Anzhen Hospital pays non établi dans la noticeÉtablissement de santé
-
Xinxiang Central Hospital pays non établi dans la noticeÉtablissement de santé
-
Xinxiang University pays non établi dans la noticeUniversité ou école supérieure
-
Shanghai Jiao Tong University Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
Henan University, Department of Pharmacy — Zhengzhou University et Henan Provincial People's Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.